Artes Biotechnology  GmbH  
HomeAbout ARTESTechnologiesOfferProductsContact   
  Artes Biotechnology GmbH | Contract R&D Services

Artes Biotechnology GmbH | Contract R&D Services

Artes Biotechnology GmbH | Contract R&D Services
ARTES Biotechnology GmbH

Biotechnological Processes and Products for Today and Tomorrow
ARTES Biotechnology is a well established development partner for recombinant protein production. Several bio-pharmaceutical products and industrial enzymes have been successfully introduced worldwide in the market by our clients and licensees.

ARTES Biotechnology delivers safe, robust and cost efficient protein production based on microbial cell lines including yeast (Hansenula polymorpha, syn. Pichia angusta) and bacteria (E. coli).

Our unique virus like particle (VLP) platform is applied for development of safe and affordable vaccines.

ARTES´ proprietary technologies ensure freedom-to-operate and reliable, competitive production. WHO recommendation, international registration, FDA approval and GRAS certification are part of the track record achieved in our international collaborations.

Large scale manufacturing and full analytics in accordance with cGMP guidelines are warranted in collaboration with a network of industrial partners.


A wide range of processes and products is available in our portfolio for immediate technology transfer.


New cell lines and processes for your product of interest are developed specifically to meet your demands.

Artes Biotechnology GmbH | Contract R&D Services.

06.10.2014 ARTES, instrAction and Q-Biologicals Join Forces for Veterinary Vaccine Development
Under the title:” development of a virus-like-particle (VLP) based vaccine platform and stable formulation especially suited for the veterinary applications”, in short “Plurivax”, the EU cooperation is part of the recent 8th EuroTransBio call and will be funded for a three year period supported by the German Federal Ministry of Education and Research (BMBF) and the Flanders (Belgium) agency for Innovation by Science and Technology (IWT)
The intent of “Plurivax” is to develop a stable production platform and an adapted high-quality process to have an effective and usable integrated best practice suitable for several veterinary vaccines.The platform resulting from this project will be the first of its kind in veterinary application and thus opens access to a huge market. A robust, inexpensive vaccine will reduce the need for antibiotic treatment of food animals, thereby directly reducing production costs and improving quality of life for the food animal itself and for the consumer.
“ARTES VLP platform METAVAX® has already been applied to the development of adjuvant-free vaccines against different diseases like avian and swine flu, malaria and HIV. Our yeast expression host Hansenula is the preferred technology for affordable mass vaccination and is recommended by the WHO for mass vaccinations. Together, our platforms build an excellent approach to low-cost mass production of safe and effective vaccines”, Michael Piontek, Managing Director of ARTES.
Annie Van Broekhoven, CEO Q-Biologicals comments: “We will employ our know-how and expertise in the field of bioprocess development, manufacturing and formulation of recombinant antigens to develop a robust production process for VLP based vaccines. We are confident that we will succeed in shortening the process development times considerably, and in doing so drive down development costs and support rapid market introduction.”
“We will contribute our tailor made but competitively priced platform purification process to this cost sensitive production processes. Our proprietary chromatography phase technology, already being used for purification of commercial biopharmaceuticals and small molecule APIs, allows specific binding of target molecules and can be transferred to almost every chromatographic carrier substrate”, Peter Kallien, CFO of instrAction.


Top of Page
  Copyright by Artes Biotechnology GmbH 2013